For research use only. Not for therapeutic Use.
(S)-Linagliptin(CAT: C000248) is a significant compound in the field of pharmaceutical chemistry. It is a selective inhibitor of dipeptidyl peptidase-4 (DPP-4) and is primarily utilized in the treatment of type 2 diabetes mellitus. By inhibiting DPP-4, (S)-Linagliptin enhances the levels of incretin hormones, such as glucagon-like peptide-1 (GLP-1), leading to improved glycemic control. This pharmaceutical agent plays a pivotal role in managing blood glucose levels in diabetic patients, ultimately reducing the risk of complications associated with the disease.
| Catalog Number | C000248 |
| CAS Number | 668270-11-9 |
| Synonyms | 8-[(3S)-3-Amino-1-piperidinyl]-7-(2-butyn-1-yl)-3,7-dihydro-3-methyl-1-[(4-methyl-2-quinazolinyl)methyl]-1H-purine-2,6-dione |
| Molecular Formula | C₂₅H₂₈N₈O₂ |
| Purity | ≥95% |
| Solubility | Chloroform (Slightly), DMSO (Slightly), Methanol (Slightly) |
| Appearance | Off-White to Dark Yellow Solid |
| Storage | 4°C |
| Reference | Prabavathy, N. et al.: Int. J. Pharm. Bio. Sci., 2, 438 (2011); Deacon, C.F.: Diab. Obes. Metab., 13, 7 (2011); |
